Prognostic value of neutrophil‐to‐lymphocyte ratio in patients with metastatic castration‐resistant prostate cancer receiving prostate‐specific membrane antigen targeted radionuclide therapy
The Prostate · 2023
DOI: 10.1002/pros.24597 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2023. Verfasst von Judith Stangl-Kremser und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Background
Neutrophil count:lymphocyte count ratio (NLR) may be a prognostic factor for men with advanced prostate cancer. We hypothesized that it is associated with prostate‐specific antigen (PSA) response and survival in men treated with prostate‐specific membrane antigen (PSMA)‐targeted radionuclide therapy (TRT).
Methods
Data of 180 men with metastatic castration‐resistant prostate cancer (mCRPC) who were treated in sequential prospective radionuclide clinical trials from 2002 to 2021 (utilizing 177Lu‐J591, 90Y‐J591, 177Lu‐PSMA‐617, or 225Ac‐J591) were retrospectively analyzed. We used a logistic regression to determine the association between NLR and ≥50% PSA decline (PSA50) and a Cox proportional hazards model to investigate the association between NLR and overall survival (OS).
Results
A total of 94 subjects (52.2%) received 177Lu‐J591, 51 (28.3%) 177Lu‐PSMA‐617, 28 (15.6%) 225Ac‐J591, and 7 (3.9%) 90Y‐J591. The median NLR of 3.75 was used as cut‐off (low vs. high NLR; n = 90, respectively). On univariate analysis, NLR was not associated with PSA50 (HR 1.08; 95% confidence interval [CI] 0.99–1.17, p = 0.067). However, it was associated with worse OS (hazard ratio [HR] 1.06, 95% CI 1.02–1.09, p = 0.002), also after controlling for circulating tumor cell count and cancer and leukemia group B risk group (HR 1.05; 95% CI 1.003–1.11, p = 0.036). Men with high NLR were at a higher hazard of death from all causes (HR 1.43, 95% CI 1.05–1.94, p = 0.024).
Conclusions
NLR provides prognostic information in the setting of patients with mCRPC receiving treatment with PSMA‐TRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Weill Cornell Medicine, New York, New York, USA.
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.
- Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
- Department of Radiology, Division of Molecular Imaging and Therapeutics, Weill Cornell Medicine, New York, New York, USA.
- Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York, USA.
ORCID-Profile: Jones T Nauseef
Zitieren
APA
Stangl-Kremser, J., Sun, M., Ho, B., Thomas, J., Nauseef, J. T., Osborne, J. R., Molina, A., Sternberg, C. N., Nanus, D. M., Bander, N. H., & Tagawa, S. (2023). Prognostic value of neutrophil‐to‐lymphocyte ratio in patients with metastatic castration‐resistant prostate cancer receiving prostate‐specific membrane antigen targeted radionuclide therapy. The Prostate. https://doi.org/10.1002/pros.24597
Vancouver
Stangl-Kremser J, Sun M, Ho B, Thomas J, Nauseef JT, Osborne JR, et al. Prognostic value of neutrophil‐to‐lymphocyte ratio in patients with metastatic castration‐resistant prostate cancer receiving prostate‐specific membrane antigen targeted radionuclide therapy. The Prostate. 2023. doi:10.1002/pros.24597
BibTeX
@article{StanglKremser2023,
author = {Stangl-Kremser, Judith and Sun, Michael and Ho, Benedict and Thomas, Joseph and Nauseef, Jones T and Osborne, Joseph R and Molina, Ana and Sternberg, Cora N and Nanus, David M and Bander, Neil H and Tagawa, Scott},
title = {Prognostic value of neutrophil‐to‐lymphocyte ratio in patients with metastatic castration‐resistant prostate cancer receiving prostate‐specific membrane antigen targeted radionuclide therapy},
journal = {The Prostate},
year = {2023},
doi = {10.1002/pros.24597}
}
EUVIMED